Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer (Q33384951)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer |
scientific article |
Statements
1 reference
Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer (English)
1 reference
I Vergote
1 reference
N Finkler
1 reference
J del Campo
1 reference
A Lohr
1 reference
J Hunter
1 reference
D Matei
1 reference
J Kavanagh
1 reference
J B Vermorken
1 reference
L Meng
1 reference
M Jones
1 reference
G Brown
1 reference
S Kaye
1 reference
ASSIST-1 Study Group
1 reference
8 June 2009
1 reference
1 reference
45
1 reference
13
1 reference
2324-2332
1 reference
Identifiers
1 reference
1 reference